TLC gains US/EU orphan status for liver cancer drug
This article was originally published in Scrip
The Taiwanese drug delivery firm Taiwan Liposome Company (TLC) has been granted orphan status in both the US and EU for its pipeline oncology product Lipotecan (TLC388), for the treatment of hepatocellular carcinoma (HCC).
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.